Hims & Hers Health, Inc. $HIMS Shares Purchased by True Vision MN LLC

True Vision MN LLC grew its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 3.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,376 shares of the company’s stock after acquiring an additional 328 shares during the quarter. True Vision MN LLC’s holdings in Hims & Hers Health were worth $467,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Northern Trust Corp increased its holdings in shares of Hims & Hers Health by 19.5% during the first quarter. Northern Trust Corp now owns 2,435,512 shares of the company’s stock valued at $71,969,000 after acquiring an additional 397,310 shares in the last quarter. Yong Rong HK Asset Management Ltd increased its holdings in shares of Hims & Hers Health by 41.2% during the first quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company’s stock valued at $70,920,000 after acquiring an additional 700,100 shares in the last quarter. Nuveen LLC acquired a new position in shares of Hims & Hers Health during the first quarter valued at about $58,403,000. BIT Capital GmbH increased its holdings in shares of Hims & Hers Health by 7.4% during the first quarter. BIT Capital GmbH now owns 1,642,493 shares of the company’s stock valued at $48,536,000 after acquiring an additional 112,949 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in shares of Hims & Hers Health by 1.2% during the first quarter. Bank of New York Mellon Corp now owns 1,260,292 shares of the company’s stock valued at $37,242,000 after acquiring an additional 15,339 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

Shares of NYSE HIMS opened at $54.68 on Tuesday. The business’s 50 day moving average price is $51.39 and its 200 day moving average price is $47.49. The firm has a market cap of $12.36 billion, a P/E ratio of 68.35, a P/E/G ratio of 3.55 and a beta of 2.25. Hims & Hers Health, Inc. has a 52 week low of $17.36 and a 52 week high of $72.98. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The company had revenue of $544.83 million during the quarter, compared to analysts’ expectations of $550.06 million. During the same quarter in the prior year, the company posted $0.06 EPS. The company’s revenue for the quarter was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Irene Becklund sold 8,410 shares of the company’s stock in a transaction that occurred on Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total value of $424,705.00. Following the sale, the insider owned 1,418 shares in the company, valued at approximately $71,609. This represents a 85.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Soleil Boughton sold 2,637 shares of the company’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $58.79, for a total value of $155,029.23. Following the completion of the sale, the insider owned 163,767 shares in the company, valued at approximately $9,627,861.93. This represents a 1.58% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,611,146 shares of company stock worth $83,026,206. Corporate insiders own 17.71% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on HIMS shares. UBS Group set a $30.00 price objective on shares of Hims & Hers Health in a report on Monday, June 23rd. Needham & Company LLC restated a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Canaccord Genuity Group reiterated a “buy” rating and issued a $68.00 target price on shares of Hims & Hers Health in a research report on Friday, September 12th. Zacks Research lowered Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Finally, Citigroup reiterated a “sell” rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Two analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $38.92.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.